MEDIFAST, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.59 USD | +5.58% |
|
+9.02% | -47.13% |
| 20/02 | Medifast, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 20/02 | Transcript : Medifast, Inc., Q4 2023 Earnings Call, Feb 20, 2024 |
Summary
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.26 for the 2024 fiscal year.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's earnings growth outlook lacks momentum and is a weakness.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company does not generate enough profits, which is an alarming weak point.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Food Processing
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -47.13% | 365M | C- | ||
| +11.32% | 7.78B | D+ | ||
| +1.64% | 7.38B | C- | ||
| +10.50% | 6.52B | - | ||
| -6.69% | 3.67B | D | ||
| -13.13% | 3.44B | B- | ||
| -10.10% | 1.17B | - | - | |
| +8.34% | 934M | - | ||
| -42.79% | 879M | B+ | ||
| -19.65% | 836M | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- MED Stock
- Ratings Medifast, Inc.
